frontotemporal-lobar

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 76/100

   Plasma p-tau217 and neurofilament/p-tau217 ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration

   ✓ Peer-reviewed alzhub usefulness score 76 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025-01-08 · Biomarkers

   Plasma p-tau 217 and the NfL/p-tau 217 ratio are promising non-invasive biomarkers for differentiating AD from FTLD, suggesting their use as a potential alternative to traditional diagnostic methods.

   • Biomarkers
   • Other Dementias
2. 62/100

   Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration

   ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Journal of neurology, neurosurgery, and psychiatry · 2020-07-01 · Biomarkers

   The assessment of serum NfL and p-Tau 181 may provide a comprehensive view of FTLD, aiding in the differential diagnosis, in staging disease severity and in defining survival probability.

   • Biomarkers
   • Other Dementias
   • Diagnosis
3. 57/100

   Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration

   ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of Alzheimer's disease : JAD · 2020-01-01 · Biomarkers

   Serum GFAP is increased in FTLD, correlates with cognition and GABAergic deficits, and thus shows promise as a biomarker of disease severity in FTLD.

   • Biomarkers
   • Other Dementias
4. 53/100

   Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders

   ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of neurology · 2019-10-08 · Biomarkers

   Due to the significant clinical overlap between frontotemporal lobar degeneration (FTLD) spectrum disorders and late-onset primary psychiatric disorders (PPD), diagnostic biomarkers reflecting the different underlying pathophysiologies are urgently needed.

   • Biomarkers
   • Other Dementias
5. 78/100

   Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study

   ✓ Peer-reviewed alzhub usefulness score 78 out of 100. The Lancet. Neurology · 2018-04-30 · Genetics

   The effect of genome-wide significant variants at the GFRA2 locus on expression of GFRA2 was assessed using mRNA expression studies in cerebellar tissue samples from the Mayo Clinic brain bank.

   • Genetics
6. 86/100

   Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration

   ✓ Peer-reviewed alzhub usefulness score 86 out of 100. Acta neuropathologica · 2014-06-05 · Genetics

   Mutations in the gene coding for Sequestosome 1 (SQSTM1) have been genetically associated with amyotrophic lateral sclerosis (ALS) and Paget disease of bone.

   • Genetics
   • Other Dementias
7. 40/100

   Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders

   ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Brain : a journal of neurology · 2003-04-01 · Biomarkers

   Formalin-fixed brain specimens from sporadic cases with frontotemporal dementia (eight with tau-positive Pick bodies, five with frontotemporal lobar degeneration without inclusions) were compared with those from non-diseased controls (n = 5).

   • Other Dementias

All topic tags with their study counts